[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635418":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":30,"locations":10,"responsibleParty":38,"collaborators":40,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":10},{"fullName":5,"class":6},"Hunter College of City University of New York","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Crossover design: Group 1 initial Intervention - Ipsilon musical tool",null,"Group 1 starts with the musical tool for 15 minutes x 7 days",[13],"Behavioral: Musical tool (Ipsilon)",{"label":15,"type":10,"description":16,"interventionNames":10},"Crossover design: Control arm starts without any intervention.","The control arm starts with no intervention.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"BEHAVIORAL","Musical tool (Ipsilon)","The musical tool to assess cognitive function",[9],[24,28],{"name":25,"affiliation":26,"role":27},"Rachel Galioto, PhD","Cleveland Clinic, MS Mellen Center","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":5,"role":27},"Aliza Ben-Zacharia, PhD, DNP",[31,35],{"name":29,"role":32,"phone":33,"phoneExt":10,"email":34},"CONTACT","16462262616","ab1288@hunter.cuny.edu",{"name":36,"role":32,"phone":10,"phoneExt":10,"email":37},"William El Samuels, PhD","ws1114@hunter.cuny.edu",{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[41,43],{"name":42,"class":6},"The Cleveland Clinic",{"name":44,"class":45},"Genentech, Inc.","INDUSTRY","100635418","cognitive-musical-screening-and-therapeutic-innovation-in-multiple-sclerosis-100635418",false,"NCT07552428","Cognitive Musical Screening and Therapeutic Innovation in Multiple Sclerosis","Neurocognitive Musical Screening and Therapeutic Innovation: A Crossover Randomized Controlled Pilot Study","MS","Inclusion Criteria:\n\n* diagnosed with multip\\[le sclerosis (MS)\n* aged 18 and older\n* speak fluent English\n\nExclusion Criteria:\n\n* Mental incapacity\u002Fmajor depression or psychiatric illness as determined by the neurology team and a score ≥11 on the Patient Health Questionnaire-9 (PHQ9)\n* Neurological conditions (other than MS) or medical illnesses that affect cognitive function (i.e., Alzheimer's disease, stroke)\n* On psychoactive medications or medications that may influence cognition (e.g. Aricept, Adderall) or active substance abuse\n* Professional musician (≥2 years formal training in last 5 years or ≥ 2 hours\u002Fweek of currently playing a musical instrument)\n* Severe vision\u002Fhearing impairments precluding assessments: color blindness, considering the diverse colors featured on the Ipsilon tool.","ALL","18 Years",{"count":57,"type":58},32,"ESTIMATED","OBSERVATIONAL","This pilot study evaluates the effectiveness of screening and improving cognitive function in patients with multiple sclerosis (MS) using a musical tool, the Ipsilon. The Ipsilon performance will be compared with established neuropsychological assessments, including the Minimal Assessment of Cognitive Function in MS (MACFIMS) and the Processing Speed Test (PST). Thirty-two participants will be enrolled in a crossover design: half will complete the Ipsilon musical test for 15 minutes daily for seven consecutive days, while the other half will begin with no intervention before switching sequences. Participants will undergo screening for depression, colorblindness, musical background, and upper extremity function. Primary outcomes include evaluating whether the Ipsilon more reliably predicts cognitive domains measured by MACFIMS than the PST and assessing its potential to improve cognitive function. Secondary outcomes will examine associations with work functioning and quality of life.",[62],"Multiple Sclerosis",[52,64,65],"Cognitive Function","Musical Tool","NOT_YET_RECRUITING","2026-04-20",{"date":69,"type":70},"2026-04-27","ACTUAL",{"date":72,"type":58},"2026-10-01",{"date":74,"type":58},"2028-12-31",{"name":5,"class":6}]